Brief: Shenzhen Hepalink Pharmaceutical Sees HY Net Profit Attributable RMB98.0 Mln-RMB127.0 Mln
14/07/2023 11:11
July 14 (Reuters) - Shenzhen Hepalink Pharmaceutical
Group Co Ltd 002399.SZ :
* SEES NET PROFIT ATTRIBUTABLE RMB98.0 MILLION TO RMB127.0
MILLION
FOR SIX MONTHS
* EXPECTED RESULT AS HEPARIN INDUSTRY CONTINUED TO FACE
CHALLENGES
OF DESTOCKING IN END MARKETS, AMONG OTHERS
* SEES NET PROFIT AFTER NON-RECURRING PROFIT OR LOSS RMB54.0
MILLION TO RMB81.0 MILLION FOR HY
Further company coverage: 002399.SZ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA